Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 1;7(1):7-19.
doi: 10.1086/689750. eCollection 2017 Mar.

Addressing the challenges of phenotyping pediatric pulmonary vascular disease

Affiliations
Review

Addressing the challenges of phenotyping pediatric pulmonary vascular disease

Kara N Goss et al. Pulm Circ. .

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Pulm Circ. 2017 Apr-Jun;7(2):559. doi: 10.1177/2045893217706334. Pulm Circ. 2017. PMID: 28597768 Free PMC article. No abstract available.

Abstract

Pediatric pulmonary vascular disease (PVD) and pulmonary hypertension (PH) represent phenotypically and pathophysiologically diverse disease categories, contributing substantial morbidity and mortality to a complex array of pediatric conditions. Here, we review the multifactorial nature of pediatric PVD, with an emphasis on improved recognition, phenotyping, and endotyping strategies for pediatric PH. Novel tailored approaches to diagnosis and treatment in pediatric PVD, as well as the implications for long-term outcomes, are highlighted.

Keywords: childhood; long-term outcomes; pulmonary hypertension; registry studies.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Diverse and interactive factors contributing to pulmonary vascular disease in pediatrics.
Fig. 2.
Fig. 2.
Developmental lung diseases associated with neonatal pulmonary hypertension, including Down syndrome (left panel), bronchopulmonary dysplasia (middle panel), and alveolar capillary dysplasia (right panel). In addition to hypertensive remodeling of small pulmonary arteries (denoted by arrows in each panel), these disorders are further characterized by decreased alveolarization, abnormal lung vascular growth, and prominent intrapulmonary vessels (bronchopulmonary or venous, as noted by V in right panel, alveolar capillary dysplasia).
Fig. 3.
Fig. 3.
Factors associated with survival in pediatric pulmonary hypertensive vascular disease from the Spanish Registry highlight the importance of large registry studies for uncommon diseases such as pediatric pulmonary hypertension. (Reprinted with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society. Del Cerro Marin MJ, Sabate Rotes A, Rodriguez Ogando A, et al. 2014. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry. Am J Respir Crit Care Med 190: 1421–1429. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.)
Fig. 4.
Fig. 4.
Chest X-ray (left panel) and CT angiography demonstrating pulmonary vein stenosis in an infant with severe bronchopulmonary dysplasia and pulmonary hypertension.
Fig. 5.
Fig. 5.
Early life pulmonary vascular development impacts adult pulmonary vascular endowment and risk for pulmonary hypertension.

References

    1. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012; 122: 4306–4313. - PMC - PubMed
    1. Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol 2013; 62: D117–126. - PubMed
    1. Abman SH, Raj U. Towards improving the care of children with pulmonary hypertension: The rationale for developing a Pediatric Pulmonary Hypertension Network. Prog Pediatr Cardiol 2009; 27: 3–6. - PMC - PubMed
    1. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: Guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132: 2037–2099. - PubMed
    1. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125: 324–334. - PubMed

LinkOut - more resources